Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Maravai LifeSciences Holdings's annualized net income for the quarter that ended in Mar. 2026 was $-14.9 Mil. Maravai LifeSciences Holdings's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $-65.7 Mil. Therefore, Maravai LifeSciences Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was N/A%.
The historical rank and industry rank for Maravai LifeSciences Holdings's Return-on-Tangible-Equity or its related term are showing as below:
During the past 8 years, Maravai LifeSciences Holdings's highest Return-on-Tangible-Equity was 701.33%. The lowest was 0.00%. And the median was 701.33%.
MRVI's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.21 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Maravai LifeSciences Holdings Return-on-Tangible-Equity Related Terms
Maravai LifeSciences Holdings Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MRVI vs LBRX, SLDB, JANX: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Maravai LifeSciences Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maravai LifeSciences Holdings Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Maravai LifeSciences Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
Maravai LifeSciences Holdings (MRVI) has a Return-on-Tangible-Equity of 0.00% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Maravai LifeSciences Holdings and its competitors. According to the industry distribution chart, Maravai LifeSciences Holdings ranks #999999 out of 1195 companies in the Biotechnology industry.
Is Maravai LifeSciences Holdings' Return-on-Tangible-Equity too high?
Maravai LifeSciences Holdings' current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Maravai LifeSciences Holdings ranks #999999 out of 1195 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Maravai LifeSciences Holdings has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Maravai LifeSciences Holdings' Return-on-Tangible-Equity compare to LBRX and SLDB?
According to the Biotechnology industry distribution chart, Maravai LifeSciences Holdings ranks #999999 out of 1195 companies for Return-on-Tangible-Equity. This places Maravai LifeSciences Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Maravai LifeSciences Holdings and its competitors. Maravai LifeSciences Holdings's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maravai LifeSciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Maravai LifeSciences Holdings (MRVI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.82, compared to a current price of $5.77 — trading 50.9% above its estimated fair value. The current Return-on-Tangible-Equity is 0.00%. Maravai LifeSciences Holdings' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Maravai LifeSciences Holdings (MRVI), the current Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maravai LifeSciences Holdings (MRVI) Overvalued in 2026?
Based on GuruFocus' analysis, Maravai LifeSciences Holdings stock appears to be overvalued.
The current stock price of $5.77 is trading 50.9% above its estimated GF Value™ of $3.82.
GuruFocus considers Maravai LifeSciences Holdings to be Significantly Overvalued.
Key valuation signals for MRVI:
Return-on-Tangible-Equity: 0.00%
GF Value™: $3.82 vs. price of $5.77 (50.9% above fair value)
No single metric tells the full story. See the MRVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maravai LifeSciences Holdings Business Description
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
62GF Score
Get the complete analysis for MRVI
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MRVI has been successfully added to your 
